ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes

Anja Soldan, Corinne Pettigrew, Anne M. Fagan, Suzanne E. Schindler, Abhay R Moghekar, Christopher Fowler, Qiao Xin Li, Steven J. Collins, Cynthia Carlsson, Sanjay Asthana, Colin L. Masters, Sterling Johnson, John C. Morris, Marilyn Albert, Alden L Gross

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To examine the long-term cognitive trajectories of individuals with normal cognition at baseline and distinct amyloid/tau/neurodegeneration (ATN) profiles. METHODS: Pooling data across 4 cohort studies, 814 cognitively normal participants (mean baseline age = 59.6 years) were classified into 8 ATN groups using baseline CSF levels of β-amyloid 1-42 as a measure of amyloid (A), phosphorylated tau 181 as a measure of tau (T), and total tau as a measure of neurodegeneration (N). Cognitive performance was measured using a previously validated global factor score and with the Mini-Mental State Examination. We compared the cognitive trajectories across groups using growth curve models (mean follow-up time = 7 years). RESULTS: Using different model formulations and cut points for determining biomarker abnormality, only the group with abnormal levels of amyloid, tau, and neurodegeneration (A+T+N+) showed consistently greater cognitive decline than the group with normal levels of all biomarkers (A-T-N-). Replicating prior findings using the 2011 National Institute on Aging-Alzheimer's Association/suspected non-Alzheimer disease pathophysiology schema, only individuals with abnormal levels of both amyloid and phosphorylated tau 181 or total tau (stage 2) showed greater cognitive decline than those with normal biomarker levels (stage 0). CONCLUSION: The results are consistent with the hypothesis that both elevated brain amyloid and neurofibrillary tangles are necessary to observe accelerated neurodegeneration, which in turn leads to cognitive decline.

Original languageEnglish (US)
Pages (from-to)e1567-e1579
JournalNeurology
Volume92
Issue number14
DOIs
StatePublished - Apr 2 2019

Fingerprint

Amyloid
Biomarkers
National Institute on Aging (U.S.)
Neurofibrillary Tangles
Cognition
Meta-Analysis
Cohort Studies
Brain
Growth
Cognitive Dysfunction

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. / Soldan, Anja; Pettigrew, Corinne; Fagan, Anne M.; Schindler, Suzanne E.; Moghekar, Abhay R; Fowler, Christopher; Li, Qiao Xin; Collins, Steven J.; Carlsson, Cynthia; Asthana, Sanjay; Masters, Colin L.; Johnson, Sterling; Morris, John C.; Albert, Marilyn; Gross, Alden L.

In: Neurology, Vol. 92, No. 14, 02.04.2019, p. e1567-e1579.

Research output: Contribution to journalArticle

Soldan, A, Pettigrew, C, Fagan, AM, Schindler, SE, Moghekar, AR, Fowler, C, Li, QX, Collins, SJ, Carlsson, C, Asthana, S, Masters, CL, Johnson, S, Morris, JC, Albert, M & Gross, AL 2019, 'ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes', Neurology, vol. 92, no. 14, pp. e1567-e1579. https://doi.org/10.1212/WNL.0000000000007248
Soldan, Anja ; Pettigrew, Corinne ; Fagan, Anne M. ; Schindler, Suzanne E. ; Moghekar, Abhay R ; Fowler, Christopher ; Li, Qiao Xin ; Collins, Steven J. ; Carlsson, Cynthia ; Asthana, Sanjay ; Masters, Colin L. ; Johnson, Sterling ; Morris, John C. ; Albert, Marilyn ; Gross, Alden L. / ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. In: Neurology. 2019 ; Vol. 92, No. 14. pp. e1567-e1579.
@article{558253769b6f4de5ad37144440618160,
title = "ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes",
abstract = "OBJECTIVE: To examine the long-term cognitive trajectories of individuals with normal cognition at baseline and distinct amyloid/tau/neurodegeneration (ATN) profiles. METHODS: Pooling data across 4 cohort studies, 814 cognitively normal participants (mean baseline age = 59.6 years) were classified into 8 ATN groups using baseline CSF levels of β-amyloid 1-42 as a measure of amyloid (A), phosphorylated tau 181 as a measure of tau (T), and total tau as a measure of neurodegeneration (N). Cognitive performance was measured using a previously validated global factor score and with the Mini-Mental State Examination. We compared the cognitive trajectories across groups using growth curve models (mean follow-up time = 7 years). RESULTS: Using different model formulations and cut points for determining biomarker abnormality, only the group with abnormal levels of amyloid, tau, and neurodegeneration (A+T+N+) showed consistently greater cognitive decline than the group with normal levels of all biomarkers (A-T-N-). Replicating prior findings using the 2011 National Institute on Aging-Alzheimer's Association/suspected non-Alzheimer disease pathophysiology schema, only individuals with abnormal levels of both amyloid and phosphorylated tau 181 or total tau (stage 2) showed greater cognitive decline than those with normal biomarker levels (stage 0). CONCLUSION: The results are consistent with the hypothesis that both elevated brain amyloid and neurofibrillary tangles are necessary to observe accelerated neurodegeneration, which in turn leads to cognitive decline.",
author = "Anja Soldan and Corinne Pettigrew and Fagan, {Anne M.} and Schindler, {Suzanne E.} and Moghekar, {Abhay R} and Christopher Fowler and Li, {Qiao Xin} and Collins, {Steven J.} and Cynthia Carlsson and Sanjay Asthana and Masters, {Colin L.} and Sterling Johnson and Morris, {John C.} and Marilyn Albert and Gross, {Alden L}",
year = "2019",
month = "4",
day = "2",
doi = "10.1212/WNL.0000000000007248",
language = "English (US)",
volume = "92",
pages = "e1567--e1579",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "14",

}

TY - JOUR

T1 - ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes

AU - Soldan, Anja

AU - Pettigrew, Corinne

AU - Fagan, Anne M.

AU - Schindler, Suzanne E.

AU - Moghekar, Abhay R

AU - Fowler, Christopher

AU - Li, Qiao Xin

AU - Collins, Steven J.

AU - Carlsson, Cynthia

AU - Asthana, Sanjay

AU - Masters, Colin L.

AU - Johnson, Sterling

AU - Morris, John C.

AU - Albert, Marilyn

AU - Gross, Alden L

PY - 2019/4/2

Y1 - 2019/4/2

N2 - OBJECTIVE: To examine the long-term cognitive trajectories of individuals with normal cognition at baseline and distinct amyloid/tau/neurodegeneration (ATN) profiles. METHODS: Pooling data across 4 cohort studies, 814 cognitively normal participants (mean baseline age = 59.6 years) were classified into 8 ATN groups using baseline CSF levels of β-amyloid 1-42 as a measure of amyloid (A), phosphorylated tau 181 as a measure of tau (T), and total tau as a measure of neurodegeneration (N). Cognitive performance was measured using a previously validated global factor score and with the Mini-Mental State Examination. We compared the cognitive trajectories across groups using growth curve models (mean follow-up time = 7 years). RESULTS: Using different model formulations and cut points for determining biomarker abnormality, only the group with abnormal levels of amyloid, tau, and neurodegeneration (A+T+N+) showed consistently greater cognitive decline than the group with normal levels of all biomarkers (A-T-N-). Replicating prior findings using the 2011 National Institute on Aging-Alzheimer's Association/suspected non-Alzheimer disease pathophysiology schema, only individuals with abnormal levels of both amyloid and phosphorylated tau 181 or total tau (stage 2) showed greater cognitive decline than those with normal biomarker levels (stage 0). CONCLUSION: The results are consistent with the hypothesis that both elevated brain amyloid and neurofibrillary tangles are necessary to observe accelerated neurodegeneration, which in turn leads to cognitive decline.

AB - OBJECTIVE: To examine the long-term cognitive trajectories of individuals with normal cognition at baseline and distinct amyloid/tau/neurodegeneration (ATN) profiles. METHODS: Pooling data across 4 cohort studies, 814 cognitively normal participants (mean baseline age = 59.6 years) were classified into 8 ATN groups using baseline CSF levels of β-amyloid 1-42 as a measure of amyloid (A), phosphorylated tau 181 as a measure of tau (T), and total tau as a measure of neurodegeneration (N). Cognitive performance was measured using a previously validated global factor score and with the Mini-Mental State Examination. We compared the cognitive trajectories across groups using growth curve models (mean follow-up time = 7 years). RESULTS: Using different model formulations and cut points for determining biomarker abnormality, only the group with abnormal levels of amyloid, tau, and neurodegeneration (A+T+N+) showed consistently greater cognitive decline than the group with normal levels of all biomarkers (A-T-N-). Replicating prior findings using the 2011 National Institute on Aging-Alzheimer's Association/suspected non-Alzheimer disease pathophysiology schema, only individuals with abnormal levels of both amyloid and phosphorylated tau 181 or total tau (stage 2) showed greater cognitive decline than those with normal biomarker levels (stage 0). CONCLUSION: The results are consistent with the hypothesis that both elevated brain amyloid and neurofibrillary tangles are necessary to observe accelerated neurodegeneration, which in turn leads to cognitive decline.

UR - http://www.scopus.com/inward/record.url?scp=85064194159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064194159&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000007248

DO - 10.1212/WNL.0000000000007248

M3 - Article

C2 - 30842300

AN - SCOPUS:85064194159

VL - 92

SP - e1567-e1579

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 14

ER -